Company celebrates one year of its Forest Conservation Policy, setting out challenges to be tackled
JAKARTA, Indonesia - Wednesday, February 5th 2014 [ME NewsWire]
(BUSINESS WIRE)-- Asia Pulp & Paper Group (APP) launched its Forest Conservation Policy (FCP) Anniversary Report with a call for NGOs, Governments and businesses to work together in an effort to help tackle deforestation in Indonesia.
On February 5th 2013, APP announced a permanent end to natural forest clearance across its entire supply chain through the introduction of its FCP. Covering over 2.6 million hectares of forest concessions, APP’s FCP represented a breakthrough moment for the global protection of natural forest. The commitment is the largest and most ambitious plan for the implementation of landscape level High Conservation Value (HCV) and High Carbon Stock (HCS) principles in the world.
As HCV and HCS assessments are nearing completion, APP has begun the process of translating its findings into the Integrated Sustainable Forest Management Plans (ISFMPs), which will set out how the concessions will be run and preserved.
However, in developing these plans, the company has concluded that success in the long term will require commitment from many more of Indonesia’s forestry stakeholders.
Aida Greenbury, APP’s managing director of sustainability and stakeholder engagement, said: “We are creating management plans to ensure the viability of the 2.6 million hectares that our suppliers are responsible for. However, unless all of Indonesia’s land is properly managed too, then the forest landscape will continue to be at risk from further degradation.
“In 2014, we will finalise the largest integrated biodiversity and conservation assessments that have ever been conducted. From these assessments, we have discovered many opportunities and obstacles that we know cannot be realised or resolved by a single company.
“It is time for all parties to get active and start working together. The days of campaigning against businesses that have shown commitment to change the way they operate, as we have, should be brought to a conclusion. Now is the time to focus on the future and to develop solutions to the complex issues associated with forestry in Indonesia and to promote responsible practise.”
Scott Poynton, executive director of The Forest Trust, a non-profit organisation that is helping APP ensure its policy is translated into actual change on the ground, said: “One year in and we have a moratorium on forest clearance in all its suppliers that has proven to be effective. HCV and HCS forest assessments are being completed, a number of social conflicts are now solved, and there is real transparency in reporting progress against its policy.
“We understand that complete trust isn’t built in a day and not even in a single year, but the company is listening to concerns and is ready to continue to implement and improve its FCP implementation. APP is 100 per cent committed to zero deforestation."
As part of its one year anniversary, APP has set out the four key priorities for 2014 that must be addressed by broader industry to bring about zero deforestation. These are:
Overlapping licenses – The issue of overlapping licenses needs to be resolved by all concerned parties if we are to develop a system for governing all concession holders in Indonesia.
Community and land conflict issues – At times when the needs of communities are at odds with no-deforestation policies, an agreed and consistent way of managing the negotiation process should be developed.
Landscape management – Landscape level conservation is vital to the preservation of peatland, the habitat of key species and protection against forest fires, all of which can span several concession areas of differing uses. A cross sector approach must therefore be developed to manage entire landscapes to ensure their long term viability.
Market recognition – Policies that protect forests and peatland can only be economically viable if there is market recognition of their value. It is therefore important for the market to encourage companies to introduce and implement them.
To mark the FCP’s anniversary, APP is today hosting an event in Jakarta, at which this and other issues can be debated by panellists from APP, TFT, Greenpeace, Ekologika and NGO participants. The panel is moderated by Mongabay’s Rhett Butler.
A recording of the event will be available at www.asiapulppaper.com this week. In addition, Twitter users can follow the discussion using hashtag #APP1yrFCP.
Notes to editors:
Key highlights of the first year of FCP implementation can be found in APP’s One Year Anniversary Report, available at www.asiapulppaper.com.
ABOUT APP
Asia Pulp & Paper Group (APP) is a trade name for a group of pulp and paper manufacturing companies in Indonesia and China. The APP Group of companies is one of the world’s largest vertically integrated pulp and paper companies, with an annual combined pulp, paper, and converting products capacity of over 18 million tons. APP-Indonesia and APP-China currently market their products in more than 120 countries across six continents. The majority of APP’s production facilities are Chain-of-Custody certified by SVLK, LEI and PEFC.
APP launched its Sustainability Roadmap Vision 2020 in June 2012 and its Forest Conservation policy in February 2013, to further improve its environmental performance, biodiversity conservation, and protection of community rights. More information can be found at www.asiapulppaper.com.
Photo Caption:
Image 1: INFOGRAPHIC: Asia Pulp & Paper's (APP) Forest Conservation Policy in Numbers. February 5, 2014 marks the one year anniversary of Asia Pulp and Paper's Forest Conservation Policy (FCP) and a permanent end to natural forest clearance across its entire supply chain. (Graphic: Business Wire)
Contacts
Asia Pulp & Paper Group
Darragh Ooi, (62-21) 29650800
Global Head of Communications
darragh_ooi@app.co.id
Tuesday, February 4, 2014
22nd Century Group Delivers Additional Proprietary Research Cigarettes with Various Nicotine Levels
ME NewsWire / Business Wire
CLARENCE, N.Y. - Tuesday, February 4th 2014
22nd Century Group, Inc. (OTCQB: XXII) today announced that Goodrich Tobacco Company, its wholly-owned subsidiary, has delivered an additional 5.5 million SPECTRUM® government research cigarettes. SPECTRUM was developed by 22nd Century for NIDA, a department of the U.S. National Institutes of Health (NIH).
As the only company in the world capable of producing very low nicotine (VLN) tobacco products, 22nd Century was chosen by NIDA to supply its proprietary cigarettes as a subcontractor under a federal government contract. The main SPECTRUM product line consists of a series of cigarette styles that have a fixed “tar” yield but varying nicotine yields over a 50-fold range – from very low to high. Altogether, SPECTRUM features 24 styles, 11 regular and 13 menthol versions, with 8 different levels of nicotine content. SPECTRUMis strictly for research purposes and will not be sold as a commercial cigarette.
Including this shipment, Goodrich Tobacco has thus far delivered more than 17 million SPECTRUM cigarettes to NIDA, equating to 850,000 packs of 20 cigarettes. NIDA distributes SPECTRUM free of charge to researchers carrying out independent studies.
Many research studies are being conducted with SPECTRUM. The research includes: (i) exposure studies comparing how different nicotine levels in cigarettes affect smoking behavior and exposure to smoke compounds, (ii) smoking cessation studies, and (iii) studies to determine whether there is a threshold nicotine level in cigarettes which does not produce dependence. Most of these studies would be very difficult, if not impossible, to conduct without SPECTRUM.
22nd Century will use the results from these studies, along with its own research studies, to support two modified risk (reduced-risk) applications it plans to file with the U.S. Food and Drug administration (FDA) in 2014 for two types of cigarettes in development – BRAND A and BRAND B. Compared to commercial cigarettes, BRAND A has approximately 95% less nicotine than cigarettes previously marketed as “lights,” and BRAND B’s smoke contains an extraordinary low amount of “tar” per milligram of nicotine.
For additional information, please visit: www.xxiicentury.com
About 22nd Century Group, Inc.
22nd Century is a plant biotechnology company whose proprietary technology allows for the levels of nicotine and other nicotinic alkaloids (e.g., nornicotine, anatabine and anabasine) in the tobacco plant to be decreased or increased through genetic engineering and plant breeding. 22nd Century owns or is the exclusive licensee of 114 issued patents in 78 countries plus an additional 38 pending patent applications. Goodrich Tobacco Company, LLC and Hercules Pharmaceuticals, LLC are wholly-owned subsidiaries of 22nd Century. Goodrich Tobacco is focused on premium commercial tobacco products and potentially less harmful cigarettes. Hercules Pharmaceuticals is focused on X-22, aprescription smoking cessation aid in development.
Cautionary Note Regarding Forward-Looking Statements: This press release contains forward-looking information, including all statements that are not statements of historical fact regarding the intent, belief or current expectations of 22nd Century Group, Inc., its directors or its officers with respect to the contents of this press release. The words “may,” “would,” “will,” “expect,” “estimate,” “anticipate,” “believe,” “intend” and similar expressions and variations thereof are intended to identify forward-looking statements. We cannot guarantee future results, levels of activity or performance. You should not place undue reliance on these forward-looking statements, which speak only as of the date that they were made. These cautionary statements should be considered with any written or oral forward-looking statements that we may issue in the future. Except as required by applicable law, including the securities laws of the United States, we do not intend to update any of the forward-looking statements to conform these statements to reflect actual results, later events or circumstances, or to reflect the occurrence of unanticipated events. You should carefully review and consider the various disclosures made by us in our annual report on Form 10-K for the fiscal year ended December 31, 2013, filed on January 30, 2014, including the section entitled “Risk Factors,” and our other reports filed with the U.S. Securities and Exchange Commission which attempt to advise interested parties of the risks and factors that may affect our business, financial condition, results of operation and cash flows. If one or more of these risks or uncertainties materialize, or if the underlying assumptions prove incorrect, our actual results may vary materially from those expected or projected.
Contacts
Redington, Inc.
Tom Redingtona
203-222-7399
Permalink: http://www.me-newswire.net/news/9928/en
CLARENCE, N.Y. - Tuesday, February 4th 2014
22nd Century Group, Inc. (OTCQB: XXII) today announced that Goodrich Tobacco Company, its wholly-owned subsidiary, has delivered an additional 5.5 million SPECTRUM® government research cigarettes. SPECTRUM was developed by 22nd Century for NIDA, a department of the U.S. National Institutes of Health (NIH).
As the only company in the world capable of producing very low nicotine (VLN) tobacco products, 22nd Century was chosen by NIDA to supply its proprietary cigarettes as a subcontractor under a federal government contract. The main SPECTRUM product line consists of a series of cigarette styles that have a fixed “tar” yield but varying nicotine yields over a 50-fold range – from very low to high. Altogether, SPECTRUM features 24 styles, 11 regular and 13 menthol versions, with 8 different levels of nicotine content. SPECTRUMis strictly for research purposes and will not be sold as a commercial cigarette.
Including this shipment, Goodrich Tobacco has thus far delivered more than 17 million SPECTRUM cigarettes to NIDA, equating to 850,000 packs of 20 cigarettes. NIDA distributes SPECTRUM free of charge to researchers carrying out independent studies.
Many research studies are being conducted with SPECTRUM. The research includes: (i) exposure studies comparing how different nicotine levels in cigarettes affect smoking behavior and exposure to smoke compounds, (ii) smoking cessation studies, and (iii) studies to determine whether there is a threshold nicotine level in cigarettes which does not produce dependence. Most of these studies would be very difficult, if not impossible, to conduct without SPECTRUM.
22nd Century will use the results from these studies, along with its own research studies, to support two modified risk (reduced-risk) applications it plans to file with the U.S. Food and Drug administration (FDA) in 2014 for two types of cigarettes in development – BRAND A and BRAND B. Compared to commercial cigarettes, BRAND A has approximately 95% less nicotine than cigarettes previously marketed as “lights,” and BRAND B’s smoke contains an extraordinary low amount of “tar” per milligram of nicotine.
For additional information, please visit: www.xxiicentury.com
About 22nd Century Group, Inc.
22nd Century is a plant biotechnology company whose proprietary technology allows for the levels of nicotine and other nicotinic alkaloids (e.g., nornicotine, anatabine and anabasine) in the tobacco plant to be decreased or increased through genetic engineering and plant breeding. 22nd Century owns or is the exclusive licensee of 114 issued patents in 78 countries plus an additional 38 pending patent applications. Goodrich Tobacco Company, LLC and Hercules Pharmaceuticals, LLC are wholly-owned subsidiaries of 22nd Century. Goodrich Tobacco is focused on premium commercial tobacco products and potentially less harmful cigarettes. Hercules Pharmaceuticals is focused on X-22, aprescription smoking cessation aid in development.
Cautionary Note Regarding Forward-Looking Statements: This press release contains forward-looking information, including all statements that are not statements of historical fact regarding the intent, belief or current expectations of 22nd Century Group, Inc., its directors or its officers with respect to the contents of this press release. The words “may,” “would,” “will,” “expect,” “estimate,” “anticipate,” “believe,” “intend” and similar expressions and variations thereof are intended to identify forward-looking statements. We cannot guarantee future results, levels of activity or performance. You should not place undue reliance on these forward-looking statements, which speak only as of the date that they were made. These cautionary statements should be considered with any written or oral forward-looking statements that we may issue in the future. Except as required by applicable law, including the securities laws of the United States, we do not intend to update any of the forward-looking statements to conform these statements to reflect actual results, later events or circumstances, or to reflect the occurrence of unanticipated events. You should carefully review and consider the various disclosures made by us in our annual report on Form 10-K for the fiscal year ended December 31, 2013, filed on January 30, 2014, including the section entitled “Risk Factors,” and our other reports filed with the U.S. Securities and Exchange Commission which attempt to advise interested parties of the risks and factors that may affect our business, financial condition, results of operation and cash flows. If one or more of these risks or uncertainties materialize, or if the underlying assumptions prove incorrect, our actual results may vary materially from those expected or projected.
Contacts
Redington, Inc.
Tom Redingtona
203-222-7399
Permalink: http://www.me-newswire.net/news/9928/en
Upsolar Commits to Global Renewable Energy Fund
Company serves as seed investor to Empower; fund will deploy 200 MW of alternative energy projects worldwide
ME Newswire / Business Wire
LUXEMBOURG - Tuesday, February 4th 2014
Upsolar, a leading provider of solar PV modules, today announced its participation in Empower, an international SICAV SIF fund created to promote the deployment of renewable energy technologies. As the seed investor, Upsolar will provide an initial contribution of USD 20M, in addition to technical and market expertise.
Managed by Luxembourg-based Archeide Lux, Empower connects global investors and developers to streamline investments in renewable energy. The fund will promote the development of low-carbon electricity—including solar, wind, hydroelectric, biomass and energy efficiency projects—across Europe, Asia, North America and the Middle East.
“Upsolar’s participation in Empower is an important stepping stone toward the development of a comprehensive international renewable energy financing mechanism,” said Alessandro Bruscagin, Director of Archeide Lux. “Building from this solid foundation, we are well positioned to attract a host of forward-thinking individual and institutional partners.”
The fund is expected to reach USD 300M by 2015, with support from a wide range of small- and mid-size investors. Empower’s initial goal is to finance 200 MW in renewable energy projects featuring photovoltaic, wind, hydroelectric and biomass power plants.
“Empower offers a strong, secure opportunity for investors wishing to diversify their portfolios and get in on the ground level of a rapidly growing industry,” said Enrico Carniato, Upsolar’s Deputy Manager of Global Investment and Business Development. “As the seed investor in the fund, Upsolar reaffirms its focus on providing new incentives to facilitate the expansion of renewable energies worldwide.”
More information on Empower can be found at www.archeidesicav.lu.
About Upsolar
Upsolar develops and produces high quality solar PV modules, offering a secure long-term investment for customers around the world. Bolstered by a commitment to product R&D and support from its flexible manufacturing platforms, Upsolar ensures top-tier performance and reliability while maintaining an asset light approach to its business. All Upsolar products are backed by industry-leading product and performance guarantees to ensure superior performance over the lifetime of each system. Upsolar also champions environmental sustainability through key sponsorships and environmental initiatives. To learn more about Upsolar, its products or its sustainability efforts, please visitwww.upsolar.com.
About Archeide, SCA, SICAV FIS
This Fund is a Luxembourg SIF established in the form of a SICAV governed by the 2007 Law, the 2010 Law, the 1915 Law and the Articles. The Fund was incorporated on January 20, 2012 in the form of an SCA under the name ARCHEIDE. The Fund is registered with the Luxembourg Trade and Companies Register under number RCS Luxembourg B 166877. The deed of incorporation of the Fund is published in the Memorial number 862 dated April 2, 2012 page 41340. The general partner of the Fund is ARCHEIDE LUX, an S.à r.l. incorporated with an initial capital of twelve thousand five hundred Euros (EUR 12,500) and registered with the Luxembourg Trade and Companies Register under number RCS Luxembourg B 166767. The deed of incorporation of the Fund is published in the Memorial number 734 dated March 20, 2012 page 35224.
Like Upsolar on Facebook: facebook.com/Upsolar
Follow Upsolar on Twitter: @UpsolarGroup
Connect with Upsolar on LinkedIn: linkedin.com/company/upsolar-group
Contacts
Upsolar
Lucy Chen, +33 1 83 62 02 05
Corporate Marketing Manager
lucy.chen@upsolar.com
Antenna Group for Upsolar
Kimberly Setliff, +1 415-977-1942
upsolar@antennagroup.com
Permalink: http://me-newswire.net/news/9927/en
ME Newswire / Business Wire
LUXEMBOURG - Tuesday, February 4th 2014
Upsolar, a leading provider of solar PV modules, today announced its participation in Empower, an international SICAV SIF fund created to promote the deployment of renewable energy technologies. As the seed investor, Upsolar will provide an initial contribution of USD 20M, in addition to technical and market expertise.
Managed by Luxembourg-based Archeide Lux, Empower connects global investors and developers to streamline investments in renewable energy. The fund will promote the development of low-carbon electricity—including solar, wind, hydroelectric, biomass and energy efficiency projects—across Europe, Asia, North America and the Middle East.
“Upsolar’s participation in Empower is an important stepping stone toward the development of a comprehensive international renewable energy financing mechanism,” said Alessandro Bruscagin, Director of Archeide Lux. “Building from this solid foundation, we are well positioned to attract a host of forward-thinking individual and institutional partners.”
The fund is expected to reach USD 300M by 2015, with support from a wide range of small- and mid-size investors. Empower’s initial goal is to finance 200 MW in renewable energy projects featuring photovoltaic, wind, hydroelectric and biomass power plants.
“Empower offers a strong, secure opportunity for investors wishing to diversify their portfolios and get in on the ground level of a rapidly growing industry,” said Enrico Carniato, Upsolar’s Deputy Manager of Global Investment and Business Development. “As the seed investor in the fund, Upsolar reaffirms its focus on providing new incentives to facilitate the expansion of renewable energies worldwide.”
More information on Empower can be found at www.archeidesicav.lu.
About Upsolar
Upsolar develops and produces high quality solar PV modules, offering a secure long-term investment for customers around the world. Bolstered by a commitment to product R&D and support from its flexible manufacturing platforms, Upsolar ensures top-tier performance and reliability while maintaining an asset light approach to its business. All Upsolar products are backed by industry-leading product and performance guarantees to ensure superior performance over the lifetime of each system. Upsolar also champions environmental sustainability through key sponsorships and environmental initiatives. To learn more about Upsolar, its products or its sustainability efforts, please visitwww.upsolar.com.
About Archeide, SCA, SICAV FIS
This Fund is a Luxembourg SIF established in the form of a SICAV governed by the 2007 Law, the 2010 Law, the 1915 Law and the Articles. The Fund was incorporated on January 20, 2012 in the form of an SCA under the name ARCHEIDE. The Fund is registered with the Luxembourg Trade and Companies Register under number RCS Luxembourg B 166877. The deed of incorporation of the Fund is published in the Memorial number 862 dated April 2, 2012 page 41340. The general partner of the Fund is ARCHEIDE LUX, an S.à r.l. incorporated with an initial capital of twelve thousand five hundred Euros (EUR 12,500) and registered with the Luxembourg Trade and Companies Register under number RCS Luxembourg B 166767. The deed of incorporation of the Fund is published in the Memorial number 734 dated March 20, 2012 page 35224.
Like Upsolar on Facebook: facebook.com/Upsolar
Follow Upsolar on Twitter: @UpsolarGroup
Connect with Upsolar on LinkedIn: linkedin.com/company/upsolar-group
Contacts
Upsolar
Lucy Chen, +33 1 83 62 02 05
Corporate Marketing Manager
lucy.chen@upsolar.com
Antenna Group for Upsolar
Kimberly Setliff, +1 415-977-1942
upsolar@antennagroup.com
Permalink: http://me-newswire.net/news/9927/en
BATS Global Markets and Direct Edge Complete Merger
Creates One of World’s Largest Exchange Operators – Integration Website Launches at bats.com/edgeintegration
KANSAS CITY, Mo. & JERSEY CITY, N.J. - Monday, February 3rd 2014 [ME NewsWire]
(BUSINESS WIRE)-- BATS Global Markets, Inc. (BATS) and Direct Edge Holdings LLC (Direct Edge) today announced the completion of their merger on January 31, 2014, creating one of the world’s largest stock exchange operators.
In January, combined US market share of the BATS and Direct Edge exchanges reached 20.54% compared to US exchanges operated by NYSE Euronext (20.58%) and Nasdaq OMX (20.02%). In Europe, BATS again finished January as the largest stock exchange with market share of 22.11%.
The combined company, which will operate under the BATS Global Markets brand, is the #1 US exchange operator by market share for all exchange-traded funds as well as the top exchange for retail-driven liquidity, according to most recent data. Joe Ratterman serves as CEO with William O’Brien as President.
“Completion of the merger creates an even stronger competitor and advocate for the benefit of all market participants,” Mr. Ratterman said. “With the Direct Edge team, we are excited to embark on a new path to deliver even greater innovation and competition, challenging the status quo globally.”
Mr. O’Brien added: “With a focus on customers, we have designed the combined company to deliver meaningful value through preservation of choice, reduced costs and technological compatibility. Our products and approach make BATS a true partner with our customers, and position us to further expand our services and relationships to benefit traders, investors and issuers.”
The company today unveiled bats.com/edgeintegration, a dedicated website for its forthcoming technology integration involving the transition of the Direct Edge equities exchanges to the proprietary BATS technology platform. BATS will host a conference call detailing its integration plans for customers on February 20, 2014 and dial-in information will be posted on bats.com/edgeintegration shortly.
Financial terms will not be disclosed for the transaction. BATS Global Markets remains headquartered in the Kansas City, Mo., area, with additional offices in London and the New York City area.
About BATS Global Markets, Inc.
BATS Global Markets, Inc. is a leading global operator of securities markets, committed to Making Markets Better for traders, investors and issuers. In the US, BATS operates four stock exchanges – BZX, BYX, EDGX and EDGA – and regularly ranks as the top market for ETF and retail-driven liquidity. The company is an important listing venue for ETFs and other structured products and also operates BATS Options, a US equity options market. In Europe, BATS operates the largest pan-European equities exchange, offering trading and listing services across 15 major European markets. With its world-class proprietary technology and relentless customer focus, BATS strives to bring efficiency, transparency and fairness to market participants. The company is headquartered in Kansas City with offices in the New York area and London. Further information on BATS can be found at www.bats.com and by following us on Twitter @BATSGlobal.
Disclaimer
BATS and its affiliates do not recommend or make any representation as to possible benefits from any securities or investments, or third-party products or services. Investors should undertake their own due diligence regarding their securities and investment practices. This press release speaks only as of this date. BATS disclaims any duty to update the information herein.
Photos/Multimedia Gallery Available: http://www.businesswire.com/cgi-bin/mmg.cgi?eid=50795301&lang=en
Contacts
BATS Global Markets
Randy Williams, +1 212-378-8522
Jim Gorman, +1 201-942-8234
Stacie Fleming, +1 913-815-7193
Suzanne O’Halloran, +1 212-378-8526
Kelly Bailey, +1 913-815-7160
Hannah Randall, +44 207-012-8950
comms@bats.com
Permalink: http://me-newswire.net/news/9921/en
KANSAS CITY, Mo. & JERSEY CITY, N.J. - Monday, February 3rd 2014 [ME NewsWire]
(BUSINESS WIRE)-- BATS Global Markets, Inc. (BATS) and Direct Edge Holdings LLC (Direct Edge) today announced the completion of their merger on January 31, 2014, creating one of the world’s largest stock exchange operators.
In January, combined US market share of the BATS and Direct Edge exchanges reached 20.54% compared to US exchanges operated by NYSE Euronext (20.58%) and Nasdaq OMX (20.02%). In Europe, BATS again finished January as the largest stock exchange with market share of 22.11%.
The combined company, which will operate under the BATS Global Markets brand, is the #1 US exchange operator by market share for all exchange-traded funds as well as the top exchange for retail-driven liquidity, according to most recent data. Joe Ratterman serves as CEO with William O’Brien as President.
“Completion of the merger creates an even stronger competitor and advocate for the benefit of all market participants,” Mr. Ratterman said. “With the Direct Edge team, we are excited to embark on a new path to deliver even greater innovation and competition, challenging the status quo globally.”
Mr. O’Brien added: “With a focus on customers, we have designed the combined company to deliver meaningful value through preservation of choice, reduced costs and technological compatibility. Our products and approach make BATS a true partner with our customers, and position us to further expand our services and relationships to benefit traders, investors and issuers.”
The company today unveiled bats.com/edgeintegration, a dedicated website for its forthcoming technology integration involving the transition of the Direct Edge equities exchanges to the proprietary BATS technology platform. BATS will host a conference call detailing its integration plans for customers on February 20, 2014 and dial-in information will be posted on bats.com/edgeintegration shortly.
Financial terms will not be disclosed for the transaction. BATS Global Markets remains headquartered in the Kansas City, Mo., area, with additional offices in London and the New York City area.
About BATS Global Markets, Inc.
BATS Global Markets, Inc. is a leading global operator of securities markets, committed to Making Markets Better for traders, investors and issuers. In the US, BATS operates four stock exchanges – BZX, BYX, EDGX and EDGA – and regularly ranks as the top market for ETF and retail-driven liquidity. The company is an important listing venue for ETFs and other structured products and also operates BATS Options, a US equity options market. In Europe, BATS operates the largest pan-European equities exchange, offering trading and listing services across 15 major European markets. With its world-class proprietary technology and relentless customer focus, BATS strives to bring efficiency, transparency and fairness to market participants. The company is headquartered in Kansas City with offices in the New York area and London. Further information on BATS can be found at www.bats.com and by following us on Twitter @BATSGlobal.
Disclaimer
BATS and its affiliates do not recommend or make any representation as to possible benefits from any securities or investments, or third-party products or services. Investors should undertake their own due diligence regarding their securities and investment practices. This press release speaks only as of this date. BATS disclaims any duty to update the information herein.
Photos/Multimedia Gallery Available: http://www.businesswire.com/cgi-bin/mmg.cgi?eid=50795301&lang=en
Contacts
BATS Global Markets
Randy Williams, +1 212-378-8522
Jim Gorman, +1 201-942-8234
Stacie Fleming, +1 913-815-7193
Suzanne O’Halloran, +1 212-378-8526
Kelly Bailey, +1 913-815-7160
Hannah Randall, +44 207-012-8950
comms@bats.com
Permalink: http://me-newswire.net/news/9921/en
Cegedim Relationship Management Announces Worldwide Availability of Global Web Connector for OneKey, Accessible via the Concur App Center
Cegedim Delivers an Integrated Cloud Solution with its Leading Healthcare Professional and Organization Database, Leveraging Concur’s Market-Leading Cloud-Based Travel and Expense Platform.
PARIS - Monday, February 3rd 2014 [ME NewsWire]
(BUSINESS WIRE)-- Cegedim Relationship Management, the worldwide market leader in healthcare compliance solutions, today announced the release of a new integration in partnership with Concur. The innovative solution will help ensure any expense tied to a Healthcare Professional (HCP) or Healthcare Organization (HCO) is accurately assigned upfront in Concur using a Cegedim OneKey global ID. Data is then seamlessly integrated into Cegedim’s AggregateSpend360 - the industry’s leading aggregate spend transparency and disclosure reporting solution. Concur is the leading provider of integrated travel and expense management solutions that are trusted by more than 20 million users worldwide.
Cloud-Based Integration Brings Enhanced Compliance Capabilities to Over 73 Markets Worldwide Revised industry association codes, coupled with more stringent transparency laws across the world, have caused Life Sciences companies to increasingly monitor and disclose their financial relationships with their individual stakeholders. Since the reporting evolves at a nominative level, uniquely identifying each covered recipient is critical.
The new Cegedim integrated solution built on Concur’s Platform, seamlessly enables Concur users to access OneKey - the world’s largest database of its kind – with 13.7 million unique, telephone-verified HCPs, HCOs and affiliations with licensure identifiers. The solution ensures high quality customer and expense data, and delivers accurate transparency reports through a seamless integration with AggregateSpend360. This comprehensive data management and reporting service collects all necessary expenditure transactions, and links them to a single customer view. AggregateSpend360 then automatically generates reports to satisfy unique compliance requirements through pre-built templates according to each transparency regulation.
Available within the Concur App Center, Cegedim’s OneKey application has the ability to deliver significant efficiency to the Life Sciences industry.
“With the increasing demand for global physician spend transparency, this breakthrough is an answer to the need for real-time, automated data integration, while complying with the latest requirements that pharmaceutical companies face throughout the world,” said Diva Duong, Vice President Compliance EMEA, Cegedim Relationship Management. “Through the partnership with Concur, we can further optimize companies’ ability to meet global compliance standards with high-value and innovative services.”
“The majority of large pharmaceutical and medical device organizations around the globe use Concur’s cloud-based solutions with sophisticated attendee spend tracking functionality.” said Jigish Avalani, SVP & GM of Concur Platform and Developer Services. “Delivering this integrated cloud solution, OneKey via the Concur App Center means that joint Concur and Cegedim Life Sciences clients can gain unparalleled insights and more easily comply with increasing physician spend tracking regulations wherever they conduct business.”
About Cegedim Relationship Management:
Cegedim Relationship Management is the Life Sciences industry’s leading provider of Customer Relationship Management (CRM) solutions. Designed specifically for Life Sciences, the company’s innovative business solutions incorporate a thorough understanding of local, regional and worldwide trends. Cegedim Relationship Management enables more than 200,000 users in many of the world’s most innovative companies to stay ahead of market challenges. In addition to CRM, Cegedim Relationship Management also provides marketing, data optimization and regulatory compliance solutions in more than 80 countries. Cegedim Relationship Management is part of the France-based Cegedim S.A. Group.
To learn more, please visit:
www.CegedimRM.com. Follow Cegedim Relationship Management on LinkedIn and Twitter.
About Cegedim:
Founded in 1969, Cegedim is a global technology and services company specializing in the healthcare field. Cegedim supplies services, technological tools, specialized software, data flow management services and databases. Its offerings are targeted notably at healthcare industries, life sciences companies, healthcare professionals and insurance companies. The world leader in life sciences CRM, Cegedim is also one of the leading suppliers of strategic healthcare industry data. Cegedim employs 8,000 people in more than 80 countries and generated revenue of €902 million in 2013. Cegedim SA is listed in Paris (EURONEXT: CGM).
To learn more, please visit: www.cegedim.com. And follow Cegedim on Twitter: @CegedimGroup.
Contacts
Cegedim
Drew BUSTOS, Tel.: +1 (908) 443.2451
Cegedim Relationship Management
Global Communications
drew.bustos@cegedim.com
Aude BALLEYDIER, Tel.: +33 (0)1 49 09 68 81
Cegedim
Media Relations
aude.balleydier@cegedim.fr
PARIS - Monday, February 3rd 2014 [ME NewsWire]
(BUSINESS WIRE)-- Cegedim Relationship Management, the worldwide market leader in healthcare compliance solutions, today announced the release of a new integration in partnership with Concur. The innovative solution will help ensure any expense tied to a Healthcare Professional (HCP) or Healthcare Organization (HCO) is accurately assigned upfront in Concur using a Cegedim OneKey global ID. Data is then seamlessly integrated into Cegedim’s AggregateSpend360 - the industry’s leading aggregate spend transparency and disclosure reporting solution. Concur is the leading provider of integrated travel and expense management solutions that are trusted by more than 20 million users worldwide.
Cloud-Based Integration Brings Enhanced Compliance Capabilities to Over 73 Markets Worldwide Revised industry association codes, coupled with more stringent transparency laws across the world, have caused Life Sciences companies to increasingly monitor and disclose their financial relationships with their individual stakeholders. Since the reporting evolves at a nominative level, uniquely identifying each covered recipient is critical.
The new Cegedim integrated solution built on Concur’s Platform, seamlessly enables Concur users to access OneKey - the world’s largest database of its kind – with 13.7 million unique, telephone-verified HCPs, HCOs and affiliations with licensure identifiers. The solution ensures high quality customer and expense data, and delivers accurate transparency reports through a seamless integration with AggregateSpend360. This comprehensive data management and reporting service collects all necessary expenditure transactions, and links them to a single customer view. AggregateSpend360 then automatically generates reports to satisfy unique compliance requirements through pre-built templates according to each transparency regulation.
Available within the Concur App Center, Cegedim’s OneKey application has the ability to deliver significant efficiency to the Life Sciences industry.
“With the increasing demand for global physician spend transparency, this breakthrough is an answer to the need for real-time, automated data integration, while complying with the latest requirements that pharmaceutical companies face throughout the world,” said Diva Duong, Vice President Compliance EMEA, Cegedim Relationship Management. “Through the partnership with Concur, we can further optimize companies’ ability to meet global compliance standards with high-value and innovative services.”
“The majority of large pharmaceutical and medical device organizations around the globe use Concur’s cloud-based solutions with sophisticated attendee spend tracking functionality.” said Jigish Avalani, SVP & GM of Concur Platform and Developer Services. “Delivering this integrated cloud solution, OneKey via the Concur App Center means that joint Concur and Cegedim Life Sciences clients can gain unparalleled insights and more easily comply with increasing physician spend tracking regulations wherever they conduct business.”
About Cegedim Relationship Management:
Cegedim Relationship Management is the Life Sciences industry’s leading provider of Customer Relationship Management (CRM) solutions. Designed specifically for Life Sciences, the company’s innovative business solutions incorporate a thorough understanding of local, regional and worldwide trends. Cegedim Relationship Management enables more than 200,000 users in many of the world’s most innovative companies to stay ahead of market challenges. In addition to CRM, Cegedim Relationship Management also provides marketing, data optimization and regulatory compliance solutions in more than 80 countries. Cegedim Relationship Management is part of the France-based Cegedim S.A. Group.
To learn more, please visit:
www.CegedimRM.com. Follow Cegedim Relationship Management on LinkedIn and Twitter.
About Cegedim:
Founded in 1969, Cegedim is a global technology and services company specializing in the healthcare field. Cegedim supplies services, technological tools, specialized software, data flow management services and databases. Its offerings are targeted notably at healthcare industries, life sciences companies, healthcare professionals and insurance companies. The world leader in life sciences CRM, Cegedim is also one of the leading suppliers of strategic healthcare industry data. Cegedim employs 8,000 people in more than 80 countries and generated revenue of €902 million in 2013. Cegedim SA is listed in Paris (EURONEXT: CGM).
To learn more, please visit: www.cegedim.com. And follow Cegedim on Twitter: @CegedimGroup.
Contacts
Cegedim
Drew BUSTOS, Tel.: +1 (908) 443.2451
Cegedim Relationship Management
Global Communications
drew.bustos@cegedim.com
Aude BALLEYDIER, Tel.: +33 (0)1 49 09 68 81
Cegedim
Media Relations
aude.balleydier@cegedim.fr
Monday, February 3, 2014
TECFIDERA® (Dimethyl Fumarate) Approved in the European Union as a First-Line Oral Treatment for Multiple Sclerosis
- Biogen Idec to Begin Launching TECFIDERA in Initial EU Countries in the Coming Weeks -
CAMBRIDGE, Mass. - Monday, February 3rd 2014 [ME NewsWire]
(BUSINESS WIRE)-- TECFIDERA® (dimethyl fumarate) has been approved by the European Commission (EC) as a first-line oral treatment for people with relapsing-remitting multiple sclerosis (RRMS), the most common form of multiple sclerosis (MS). Biogen Idec (NASDAQ: BIIB) will begin to introduce TECFIDERA in initial European Union (EU) countries in the coming weeks.
TECFIDERA was first approved in the United States in March 2013 and became the country’s number one prescribed oral therapy for relapsing forms of MS after six months.1TECFIDERA was also approved in Canada and in Australia in 2013.
“TECFIDERA exemplifies our commitment to deliver innovative therapies that help people living with serious diseases,” said George A. Scangos, Ph.D., chief executive officer of Biogen Idec. “We already have seen TECFIDERA’s significant impact on transforming the standard of care for MS where it is available and are excited to quickly bring its benefits to patients in the EU as well.”
The EC approval is based on a robust clinical development program that included two global Phase 3 clinical trials, DEFINE and CONFIRM, as well as an ongoing extension study, ENDORSE, in which some patients have been followed for up to six and a half years. TECFIDERA has been clinically shown to significantly reduce important measures of disease activity, including relapses and the development of brain lesions, as well as to slow disability progression, while demonstrating a favorable safety and tolerability profile.
“As a physician, I am all too familiar with the challenges my patients experience while managing their MS. TECFIDERA may lower this burden for many because it is an oral therapy that has been proven to lessen disease activity effectively while maintaining a favorable safety profile,” said Ralf Gold, M.D., professor and chair of the Department of Neurology, St. Josef-Hospital/Ruhr-University Bochum and lead investigator of DEFINE. “Moreover, the positive experience we have had with TECFIDERA throughout its extensive clinical program gives me confidence about the benefits this oral therapy may offer my patients in the EU.”
TECFIDERA is the fourth therapy Biogen Idec offers to people living with MS.
About the TECFIDERA Phase 3 Clinical Program
The efficacy and safety of TECFIDERA were evaluated in two large, global Phase 3 clinical studies, DEFINE and CONFIRM.
In DEFINE, TECFIDERA administered twice daily significantly reduced the proportion of patients who relapsed by 49 percent (p<0.0001), the annualized relapse rate (ARR) by 53 percent (p<0.0001), and the risk of 12-week confirmed disability progression, as measured by the Expanded Disability Status Scale (EDSS), by 38 percent (p=0.0050) compared to placebo at two years. In CONFIRM, which also included an active reference comparator of glatiramer acetate (GA) compared to placebo, twice-daily TECFIDERA significantly reduced ARR by 44 percent (p<0.0001) and the proportion of patients who relapsed by 34 percent (p=0.0020) compared to placebo at two years. While not statistically significant, TECFIDERA showed a 21 percent reduction in the risk of 12-week confirmed disability progression in CONFIRM compared to placebo at two years.
In both DEFINE and CONFIRM,TECFIDERA also significantly reduced lesions in the brain compared to placebo, as measured by magnetic resonance imaging (MRI). Glatiramer acetate data in CONFIRM, compared to placebo, was consistent with EU product labeling.
The most common adverse events (AEs) associated with TECFIDERA were flushing and gastrointestinal (GI) events (i.e., diarrhea, nausea, abdominal pain, upper abdominal pain). Overall, clinical trial discontinuations due to flushing (3%) and GI events (4%) were low.
Mean lymphocyte counts decreased during the first year of treatment and then remained stable. There were no opportunistic infections in TECFIDERA-treated patients and no overall increased risk of serious infections.
About TECFIDERA®
TECFIDERA (dimethyl fumarate) gastro-resistant hard capsules are indicated for the treatment of adult patients with relapsing-remitting multiple sclerosis (RRMS). TECFIDERA has been shown to reduce multiple sclerosis (MS) relapses and MS brain lesions, as well as to slow the progression of disability, while demonstrating a favorable safety and tolerability profile. The efficacy and safety of TECFIDERA has been studied in a large, global clinical program, which includes an ongoing long-term extension study. As of September 2013, approximately 35,000 patients were being treated with TECFIDERA globally.2
It is believed that TECFIDERA provides a new approach to treating MS by activating the Nrf2 pathway, although its exact mechanism of action is not fully understood. This pathway provides a way for cells in the body to defend themselves against inflammation and oxidative stress caused by conditions like MS.
According to the EU Summary of Product Characteristics (SmPC), the starting dose of TECFIDERA is 120 mg twice a day orally. After seven days, the recommended dose should be increased to 240 mg twice a day.
The most common adverse reactions for TECFIDERA are flushing and gastrointestinal (GI) events (i.e., diarrhea, nausea, abdominal pain, upper abdominal pain), which were mostly mild or moderate in patients experiencing these reactions in clinical trials. For patients who experience these side effects, they tend to begin primarily during the first month of treatment and may continue to occur intermittently throughout treatment with TECFIDERA.
TECFIDERA may decrease lymphocyte counts. TECFIDERA has not been studied in patients with pre-existing low lymphocyte counts. A complete blood count (CBC) is recommended prior to initiating treatment. A follow up CBC is also recommended after six months of treatment, every six to 12 months thereafter and at the discretion of the physician.
Changes in renal and hepatic laboratory tests have been seen in clinical trials in patients treated with TECFIDERA. The clinical implications of these changes are unknown. Liver and kidney function tests are recommended prior to starting treatment, after three and six months of treatment, every six to 12 months thereafter and at the discretion of the physician.
TECFIDERA is not recommended during pregnancy or in women of child bearing potential not using appropriate contraception.
Additional resources on TECFIDERA are available to the media upon request.
About Biogen Idec
Through cutting-edge science and medicine, Biogen Idec discovers, develops and delivers to patients worldwide innovative therapies for the treatment of neurodegenerative diseases, hemophilia and autoimmune disorders. Founded in 1978, Biogen Idec is the world’s oldest independent biotechnology company. Patients worldwide benefit from its leading multiple sclerosis therapies. For product labeling, press releases and additional information about the Company, please visit www.biogenidec.com.
Safe Harbor
This press release contains forward-looking statements, including statements about the potential benefits and therapeutic impact of TECFIDERA. These forward-looking statements may be accompanied by such words as “anticipate,” “believe,” “could,” “estimate,” “expect,” “forecast,” “intend,” “may,” “plan,” “potential,” “project,” “target,” “will” and other words and terms of similar meaning. You should not place undue reliance on these statements. These statements involve risks and uncertainties that could cause actual results to differ materially from those reflected in such statements, including uncertainty of success in commercialization of TECFIDERA, unexpected hurdles or difficulties in launching TECFIDERA in EU countries, difficulties obtaining or changes in the availability of reimbursement for TECFIDERA, problems with our manufacturing processes and our reliance on third parties to manufacture and supply TECFIDERA, the occurrence of adverse safety events, failure to comply with government regulation, our ability to protect our intellectual property and other proprietary rights, product liability claims and the other risks and uncertainties that are described in the Risk Factors section of our most recent annual or quarterly report and in other reports we have filed with the U.S. Securities and Exchange Commission (SEC). These statements are based on our current beliefs and expectations and speak only as of the date of this press release. We do not undertake any obligation to publicly update any forward-looking statements.
1 Based on number of prescriptions from IMS NPA™ Weekly Data (27 September 2013) and Biogen Idec data on file.
2 Biogen Idec data on file.
Contacts
US MEDIA CONTACT:
Biogen Idec
Kate Niazi-Sai, +1 781-464-3260
public.affairs@biogenidec.com
EX-US MEDIA CONTACT:
Biogen Idec International
Shannon Altimari, +41 41 392 1702
publicaffairs.EU@biogenidec.com
INVESTOR CONTACTS:
Biogen Idec
Claudine Prowse, Ph.D., +1 781-464-2442
IR@biogenidec.com
Carlo Tanzi, Ph.D., +1 781-464-2442
IR@biogenidec.com
Permalink: http://www.me-newswire.net/news/9924/en
CAMBRIDGE, Mass. - Monday, February 3rd 2014 [ME NewsWire]
(BUSINESS WIRE)-- TECFIDERA® (dimethyl fumarate) has been approved by the European Commission (EC) as a first-line oral treatment for people with relapsing-remitting multiple sclerosis (RRMS), the most common form of multiple sclerosis (MS). Biogen Idec (NASDAQ: BIIB) will begin to introduce TECFIDERA in initial European Union (EU) countries in the coming weeks.
TECFIDERA was first approved in the United States in March 2013 and became the country’s number one prescribed oral therapy for relapsing forms of MS after six months.1TECFIDERA was also approved in Canada and in Australia in 2013.
“TECFIDERA exemplifies our commitment to deliver innovative therapies that help people living with serious diseases,” said George A. Scangos, Ph.D., chief executive officer of Biogen Idec. “We already have seen TECFIDERA’s significant impact on transforming the standard of care for MS where it is available and are excited to quickly bring its benefits to patients in the EU as well.”
The EC approval is based on a robust clinical development program that included two global Phase 3 clinical trials, DEFINE and CONFIRM, as well as an ongoing extension study, ENDORSE, in which some patients have been followed for up to six and a half years. TECFIDERA has been clinically shown to significantly reduce important measures of disease activity, including relapses and the development of brain lesions, as well as to slow disability progression, while demonstrating a favorable safety and tolerability profile.
“As a physician, I am all too familiar with the challenges my patients experience while managing their MS. TECFIDERA may lower this burden for many because it is an oral therapy that has been proven to lessen disease activity effectively while maintaining a favorable safety profile,” said Ralf Gold, M.D., professor and chair of the Department of Neurology, St. Josef-Hospital/Ruhr-University Bochum and lead investigator of DEFINE. “Moreover, the positive experience we have had with TECFIDERA throughout its extensive clinical program gives me confidence about the benefits this oral therapy may offer my patients in the EU.”
TECFIDERA is the fourth therapy Biogen Idec offers to people living with MS.
About the TECFIDERA Phase 3 Clinical Program
The efficacy and safety of TECFIDERA were evaluated in two large, global Phase 3 clinical studies, DEFINE and CONFIRM.
In DEFINE, TECFIDERA administered twice daily significantly reduced the proportion of patients who relapsed by 49 percent (p<0.0001), the annualized relapse rate (ARR) by 53 percent (p<0.0001), and the risk of 12-week confirmed disability progression, as measured by the Expanded Disability Status Scale (EDSS), by 38 percent (p=0.0050) compared to placebo at two years. In CONFIRM, which also included an active reference comparator of glatiramer acetate (GA) compared to placebo, twice-daily TECFIDERA significantly reduced ARR by 44 percent (p<0.0001) and the proportion of patients who relapsed by 34 percent (p=0.0020) compared to placebo at two years. While not statistically significant, TECFIDERA showed a 21 percent reduction in the risk of 12-week confirmed disability progression in CONFIRM compared to placebo at two years.
In both DEFINE and CONFIRM,TECFIDERA also significantly reduced lesions in the brain compared to placebo, as measured by magnetic resonance imaging (MRI). Glatiramer acetate data in CONFIRM, compared to placebo, was consistent with EU product labeling.
The most common adverse events (AEs) associated with TECFIDERA were flushing and gastrointestinal (GI) events (i.e., diarrhea, nausea, abdominal pain, upper abdominal pain). Overall, clinical trial discontinuations due to flushing (3%) and GI events (4%) were low.
Mean lymphocyte counts decreased during the first year of treatment and then remained stable. There were no opportunistic infections in TECFIDERA-treated patients and no overall increased risk of serious infections.
About TECFIDERA®
TECFIDERA (dimethyl fumarate) gastro-resistant hard capsules are indicated for the treatment of adult patients with relapsing-remitting multiple sclerosis (RRMS). TECFIDERA has been shown to reduce multiple sclerosis (MS) relapses and MS brain lesions, as well as to slow the progression of disability, while demonstrating a favorable safety and tolerability profile. The efficacy and safety of TECFIDERA has been studied in a large, global clinical program, which includes an ongoing long-term extension study. As of September 2013, approximately 35,000 patients were being treated with TECFIDERA globally.2
It is believed that TECFIDERA provides a new approach to treating MS by activating the Nrf2 pathway, although its exact mechanism of action is not fully understood. This pathway provides a way for cells in the body to defend themselves against inflammation and oxidative stress caused by conditions like MS.
According to the EU Summary of Product Characteristics (SmPC), the starting dose of TECFIDERA is 120 mg twice a day orally. After seven days, the recommended dose should be increased to 240 mg twice a day.
The most common adverse reactions for TECFIDERA are flushing and gastrointestinal (GI) events (i.e., diarrhea, nausea, abdominal pain, upper abdominal pain), which were mostly mild or moderate in patients experiencing these reactions in clinical trials. For patients who experience these side effects, they tend to begin primarily during the first month of treatment and may continue to occur intermittently throughout treatment with TECFIDERA.
TECFIDERA may decrease lymphocyte counts. TECFIDERA has not been studied in patients with pre-existing low lymphocyte counts. A complete blood count (CBC) is recommended prior to initiating treatment. A follow up CBC is also recommended after six months of treatment, every six to 12 months thereafter and at the discretion of the physician.
Changes in renal and hepatic laboratory tests have been seen in clinical trials in patients treated with TECFIDERA. The clinical implications of these changes are unknown. Liver and kidney function tests are recommended prior to starting treatment, after three and six months of treatment, every six to 12 months thereafter and at the discretion of the physician.
TECFIDERA is not recommended during pregnancy or in women of child bearing potential not using appropriate contraception.
Additional resources on TECFIDERA are available to the media upon request.
About Biogen Idec
Through cutting-edge science and medicine, Biogen Idec discovers, develops and delivers to patients worldwide innovative therapies for the treatment of neurodegenerative diseases, hemophilia and autoimmune disorders. Founded in 1978, Biogen Idec is the world’s oldest independent biotechnology company. Patients worldwide benefit from its leading multiple sclerosis therapies. For product labeling, press releases and additional information about the Company, please visit www.biogenidec.com.
Safe Harbor
This press release contains forward-looking statements, including statements about the potential benefits and therapeutic impact of TECFIDERA. These forward-looking statements may be accompanied by such words as “anticipate,” “believe,” “could,” “estimate,” “expect,” “forecast,” “intend,” “may,” “plan,” “potential,” “project,” “target,” “will” and other words and terms of similar meaning. You should not place undue reliance on these statements. These statements involve risks and uncertainties that could cause actual results to differ materially from those reflected in such statements, including uncertainty of success in commercialization of TECFIDERA, unexpected hurdles or difficulties in launching TECFIDERA in EU countries, difficulties obtaining or changes in the availability of reimbursement for TECFIDERA, problems with our manufacturing processes and our reliance on third parties to manufacture and supply TECFIDERA, the occurrence of adverse safety events, failure to comply with government regulation, our ability to protect our intellectual property and other proprietary rights, product liability claims and the other risks and uncertainties that are described in the Risk Factors section of our most recent annual or quarterly report and in other reports we have filed with the U.S. Securities and Exchange Commission (SEC). These statements are based on our current beliefs and expectations and speak only as of the date of this press release. We do not undertake any obligation to publicly update any forward-looking statements.
1 Based on number of prescriptions from IMS NPA™ Weekly Data (27 September 2013) and Biogen Idec data on file.
2 Biogen Idec data on file.
Contacts
US MEDIA CONTACT:
Biogen Idec
Kate Niazi-Sai, +1 781-464-3260
public.affairs@biogenidec.com
EX-US MEDIA CONTACT:
Biogen Idec International
Shannon Altimari, +41 41 392 1702
publicaffairs.EU@biogenidec.com
INVESTOR CONTACTS:
Biogen Idec
Claudine Prowse, Ph.D., +1 781-464-2442
IR@biogenidec.com
Carlo Tanzi, Ph.D., +1 781-464-2442
IR@biogenidec.com
Permalink: http://www.me-newswire.net/news/9924/en
Xaxis Agrees to Acquire Pioneering Ad Firm Bannerconnect
NEW YORK, LONDON & SITTARD, The Netherlands - Monday, February 3rd 2014 [ME NewsWire]
Deal Augments Company’s Global Offerings with Addition of Bannerconnect’s Industry-Leading Bright™ Optimization Platform and Experienced Management Team
(BUSINESS WIRE)-- Xaxis, the world's largest programmatic media and technology platform, announced today it has agreed to acquire media trading firm Bannerconnect. Headquartered in Sittard, the Netherlands, Bannerconnect is one of Europe’s top programmatic advertising specialists with a decade-long track record developing proprietary ad technology solutions to power automated campaigns for the world’s most sophisticated marketers. The acquisition will enable Xaxis to fully integrate Bannerconnect’s proprietary technology into the Xaxis audience platform, enhancing the company’s ability to deliver industry-leading results to its 2,700 clients around the world. Bannerconnect will continue under the leadership of current CEO Sebastiaan Schepers.
The deal will enhance the global capabilities of Xaxis with the addition of Bannerconnect’s talented, 40-plus person team and complementary technology offerings including the firm’s industry-leading Bright™ real-time optimization platform. Bright provides advertisers unprecedented real-time optimization and visualization of campaign performance. Today’s news follows the company’s recent announcement that it has merged with 24/7 Media and its recent acquisition of ad tech firm Crystal Semantics. In addition to augmenting the Xaxis platform, Bannerconnect will be used across trading desk initiatives within GroupM.
“Bannerconnect has created proven programmatic technology while also gaining experience developing effective campaigns for some of the world’s largest advertisers,” said Brian Lesser, CEO of Xaxis. “This acquisition will immediately enhance our technology capabilities and support our overall mission of empowering brands to reach relevant audiences wherever they access media.”
Founded in 2004, Bannerconnect pioneered ad exchange trading in Europe and, more recently, was the first European firm to effectively package multi-device synchronization solutions, allowing advertisers to coordinate online display ads with those seen on audience members’ mobile devices. In addition to its Sittard headquarters, Bannerconnect has offices in Amsterdam and London.
“Xaxis has become the global pacesetter for the programmatic industry and this deal enables us to extend our footprint and the Bright platform to a much broader, worldwide market,” said Schepers, CEO of Bannerconnect. “With programmatic ad spending projected to grow by double-digit percentages for the next several years according to eMarketer, it is an exciting time to join with the market leader to continue to bring clients the most effective solutions in the space.”
“Bannerconnect has been a longtime strategic partner for many of our agencies and the acquisition will effectively bring the company’s proprietary technology and industry-leading thought leadership in-house,” said Ruud Wanck, global chief operating officer for GroupM Interaction. “Under the Xaxis umbrella, and across GroupM, we will be able to further develop these solutions on a global level, enhancing our overall competitive advantage and extending our lead as the world’s leading player in the programmatic space.”
ABOUT XAXIS
Xaxis is a global digital media platform that programmatically connects advertisers and publishers to audiences across all addressable channels. Xaxis combines proprietary technology, unique data assets and exclusive media relationships with the brightest team of audience analysts, data scientists and software engineers. Advertisers working with Xaxis achieve higher ROI from digital marketing campaigns. Publishers deliver relevant content and advertising to new and valuable audiences. Xaxis works with over 2,700 clients across 32 markets in North America, Europe, Asia Pacific and Latin America. For more information, visit www.xaxis.com.
Contacts
Swift / Xaxis
Adrian Brophy, +44 1962 883 203
adrian.brophy@swift.co
Peter Epstein, +1 323-251-3567
peter.epstein@swift.co
Permalink: http://www.me-newswire.net/news/9916/en
Deal Augments Company’s Global Offerings with Addition of Bannerconnect’s Industry-Leading Bright™ Optimization Platform and Experienced Management Team
(BUSINESS WIRE)-- Xaxis, the world's largest programmatic media and technology platform, announced today it has agreed to acquire media trading firm Bannerconnect. Headquartered in Sittard, the Netherlands, Bannerconnect is one of Europe’s top programmatic advertising specialists with a decade-long track record developing proprietary ad technology solutions to power automated campaigns for the world’s most sophisticated marketers. The acquisition will enable Xaxis to fully integrate Bannerconnect’s proprietary technology into the Xaxis audience platform, enhancing the company’s ability to deliver industry-leading results to its 2,700 clients around the world. Bannerconnect will continue under the leadership of current CEO Sebastiaan Schepers.
The deal will enhance the global capabilities of Xaxis with the addition of Bannerconnect’s talented, 40-plus person team and complementary technology offerings including the firm’s industry-leading Bright™ real-time optimization platform. Bright provides advertisers unprecedented real-time optimization and visualization of campaign performance. Today’s news follows the company’s recent announcement that it has merged with 24/7 Media and its recent acquisition of ad tech firm Crystal Semantics. In addition to augmenting the Xaxis platform, Bannerconnect will be used across trading desk initiatives within GroupM.
“Bannerconnect has created proven programmatic technology while also gaining experience developing effective campaigns for some of the world’s largest advertisers,” said Brian Lesser, CEO of Xaxis. “This acquisition will immediately enhance our technology capabilities and support our overall mission of empowering brands to reach relevant audiences wherever they access media.”
Founded in 2004, Bannerconnect pioneered ad exchange trading in Europe and, more recently, was the first European firm to effectively package multi-device synchronization solutions, allowing advertisers to coordinate online display ads with those seen on audience members’ mobile devices. In addition to its Sittard headquarters, Bannerconnect has offices in Amsterdam and London.
“Xaxis has become the global pacesetter for the programmatic industry and this deal enables us to extend our footprint and the Bright platform to a much broader, worldwide market,” said Schepers, CEO of Bannerconnect. “With programmatic ad spending projected to grow by double-digit percentages for the next several years according to eMarketer, it is an exciting time to join with the market leader to continue to bring clients the most effective solutions in the space.”
“Bannerconnect has been a longtime strategic partner for many of our agencies and the acquisition will effectively bring the company’s proprietary technology and industry-leading thought leadership in-house,” said Ruud Wanck, global chief operating officer for GroupM Interaction. “Under the Xaxis umbrella, and across GroupM, we will be able to further develop these solutions on a global level, enhancing our overall competitive advantage and extending our lead as the world’s leading player in the programmatic space.”
ABOUT XAXIS
Xaxis is a global digital media platform that programmatically connects advertisers and publishers to audiences across all addressable channels. Xaxis combines proprietary technology, unique data assets and exclusive media relationships with the brightest team of audience analysts, data scientists and software engineers. Advertisers working with Xaxis achieve higher ROI from digital marketing campaigns. Publishers deliver relevant content and advertising to new and valuable audiences. Xaxis works with over 2,700 clients across 32 markets in North America, Europe, Asia Pacific and Latin America. For more information, visit www.xaxis.com.
Contacts
Swift / Xaxis
Adrian Brophy, +44 1962 883 203
adrian.brophy@swift.co
Peter Epstein, +1 323-251-3567
peter.epstein@swift.co
Permalink: http://www.me-newswire.net/news/9916/en
Subscribe to:
Posts (Atom)